baber/WOPTO huggingface dataset:
Patent PT-1478394-E (PT)
Title: Stabilized tnfr-fc composition comprising arginine
Inventor: GOMBOTZ WAYNE R
IPC: A61K47/10
Filed: 2003-02-27
Abstract: The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.
Patent PT-1507863-E (PT)
Title: Plasmid stabilisation in vivo
Inventor: HANAK JULIAN
IPC: C12N15/64
Filed: 2003-05-19
Abstract: This invention provides in vivo methods of maintaining a plasmid within a host cell, which is in turn within a recipient organism. In particular it relates to methods of maintaining a plasmid containing a gene useful in therapy, especially vaccination. The invention is based on modified host cells, suitable for in vivo therapeutic use, that may be used to express a therapeutically useful plasmid-borne gene, using a plasmid maintenance system that does not require the use of a plasmid-borne dominant selectable marker, but rather utilises a system of repressor titration. Methods of selecting host cells comprising the plasmid and host cells for use in these methods are also provided.
Patent PT-1913606-E (PT)
Title: Line transformer for impedance matching
Inventor: FLUHRER CHRISTOPH
IPC: H01P5/10
Filed: 2006-06-19
Abstract: The invention relates to a line transformer for impedance matching in high-frequency applications. The line transformer (1') comprises at least one first high-frequency line section (2) and a second high-frequency line section (3). At least one of the high-frequency line sections (2, 3) is surrounded by a ferrite body (12), the high-frequency line sections (2, 3) being provided in the form of microstrip lines between a first connection (10) and a second connection (11). The high-frequency line sections (2, 3, 29) have an essentially identical impedance.
Patent PT-2128973-E (PT)
Title: Starting device for at least two synchronous machines
Inventor: KELLER TOBIAS
IPC: H02J3/38
Filed: 2008-05-27
Abstract: The device has excitation units (SES, SESX) connected with excitation windings of synchronous machines (G), and connected with each other by a ring communication connection (1). A superordinate control unit (DCS) is connected with each excitation unit by the communication connection. Switch units (SSB) are connected with associated stator feed units (SSD) by the communication connection. Each stator feed unit is connected with the ring communication connection. The excitation units are connected with switch units by the connection.
Patent PT-2105143-E (PT)
Title: Pharmaceutical compositions based on salts of tiotropium and ciclesonide
Inventor: PAIRET MICHEL
IPC: A61K31/56
Filed: 2001-12-12
Abstract: A medicament (A) comprises a combination of anticholinergic agent(s) (I) and the corticosteroid ST-126 (II), optionally together with pharmaceutical auxiliaries. ACTIVITY : Antiinflammatory; Antiasthmatic; Antiallergic. MECHANISM OF ACTION : Anticholinergic.
Patent PT-2451292-E (PT)
Title: A drinkable acidified dairy product based on acid whey and a process of preparing it
Inventor: ANDERSEN CLAUS
IPC: A23C3/03
Filed: 2010-07-09
Abstract: The present invention relates to a process for the manufacturing of a drinkable acidified dairy product based on acid whey without coagulum formation after acidification, said drinkable dairy product has a casein:whey protein ratio of from 0.5:99.5 to 12:88 (w/w), wherein the process involve the direct mixing of all ingredients before acidified. In addition, the invention provides a drinkable acidified dairy product obtainable by the present process with low casein content. While having the same flavour and organoleptic characteristics as traditional drinking yoghurt, it has a different protein structure and a different composition with regard to the content of casein and whey proteins.
Patent PT-614355-E (PT)
Inventor: SPITLER LYNN E
IPC: C07K16/42
Filed: 1992-11-25
Abstract: Antitumor vaccine compositions and methods for treating tumors that express the GA733-2 antigen are disclosed. The vaccines comprise a GS733-2 antigen in a liposomal carrier.
Patent PT-643585-E (PT)
Inventor: CREASEY ABLA A
IPC: A61P29/00
Filed: 1993-04-23
Abstract: A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
Patent PT-626939-E (PT)
Inventor: BOYD EWAN CAMPBELL
IPC: C07C327/48
Filed: 1993-12-22
Abstract: Compounds of general formula (1) are described wherein Y is a halogen atom or a group -OR<1>, where R<1> is an optionally substituted alkyl group; X is -O-, -S- or -N(R<8>)-, where R<8> is a hydrogen atom or an alkyl group; R<2> is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R<3> is a hydrogen or halogen atom or an -OR<9> group, where R<9> is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group; R<4> and R<5>, which may be the same or different, is each a group (CH2)nAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one ore more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3; R<6> is a hydrogen atom or an optionally substituted alkyl group; R<7> is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof. Compounds according to the invention are potent, selective and orally active PDE IV inhibitors and are useful in the prophylaxis and treatment of asthma and other diseases. <IMAGE>
Patent PT-710448-E (PT)
Inventor: SOLZI MARIA LUISA
IPC: A23L1/164
Filed: 1995-06-20
Abstract: A biscuit is described which is free from added fats and includes from 36 to 90% by weight of cereal flakes and from 7 to 28% by weight of sugar binder. The biscuit is manufactured by baking and extrusion of selected ground cereals and flaking and mixing of the flakes with the sugar binder. The flake-binder dough, which is obtained with a moisture content of 15-30%, is finally shaped. <IMAGE>
Patent PT-738263-E (PT)
Inventor: GOUBET FRANCOIS
IPC: C07D233/78
Filed: 1995-01-04
Abstract: PCT No. PCT/FR95/00004 Sec. 371 Date Jun. 27, 1996 Sec. 102(e) Date Jun. 27, 1996 PCT Filed Jan. 4, 1995 PCT Pub. No. WO95/18794 PCT Pub. Date Jul. 13, 1995A compound in all possible racemic, enantiomeric and diastereoisomer forms of the formula   <IMAGE>   wherein Y is -O-, Z2 is -CF3, Z1 is -CN or -NO2, X is -O- or -S-, R3 is hydrogen or alkyl of 1 to 4 carbon atoms optionally substituted by at least one halogen or -CN and R4 and R5 are individually alkyl of 1 to 4 carbon atoms optionally substituted with a member of the group consisting of halogen, -OH, esterified or etherified or protected hydroxy and phenylthio optionally substituted by halogen or -OH, and wherein at least one of R4 and R5 is substituted having antiandrogenic activity.
Patent PT-783505-E (PT)
Inventor: MARTIN MISSBACH
IPC: A61P35/00
Filed: 1995-09-08
Abstract: PCT No. PCT/EP95/03536 Sec. 371 Date Mar. 19, 1997 Sec. 102(e) Date Mar. 19, 1997 PCT Filed Sep. 8, 1995 PCT Pub. No. WO96/10028 PCT Pub. Date Apr. 4, 1996The invention relates to the use of the compounds mentioned below in the therapeutic treatment of tumor diseases and other proliferative diseases, such as psoriasis, and to novel compounds of that type. The compounds are compounds of formula I   n is not 0, R is one or more substituents selected from halogen, alkyl, trifluoromethyl and alkoxy; and R1 and R2 are each independently of the other alkyl, or phenyl that is unsubstituted or substituted by halogen, trifluoromethyl, alkyl or by alkoxy, it also being possible for one of the two radicals R1 and R2 to be hydrogen, or R1 and R2 together form an alkylene chain having from 2 to 5 carbon atoms that is unsubstituted or substituted by alkyl; or salts thereof. Compounds of formula I inhibit protein kinases, for example the tyrosine protein kinase of the receptor for the epidermal growth factor, EGF.
Patent PT-957173-E (PT)
Inventor: KENICHI HIGASHIYAMA
IPC: A23L33/00
Filed: 1997-08-27
Abstract: A process for production of unsaturated fatty acid-containing oils which is characterized by culturing a microorganism belonging to the genus Mortierella subgenus Mortierella in a medium containing a nitrogen source derived from soybean, and collecting the unsaturated fatty acid-containing oil from the cultured product. The oils are obtained with a low 24,25-methylenecholest-5-en-3 beta -ol content.
Patent PT-1007999-E (PT)
Title: Polarisation asymmetric active optical waveguide, method of its production, and its uses
Inventor: KRISTENSEN MARTIN
IPC: H01S3/067
Filed: 1998-02-13
Abstract: A method of producing an active optical waveguide having asymmetric polarization, said method comprising the steps of (a) providing an active optical waveguide (10) comprising: (i) a transverse refractive index profile (21) comprising a guiding region (11), an intermediate region (13), and a non-guiding region (12); (ii) a transverse photorefractive dopant profile (31) comprising a constant or graded photorefractive dopant concentration within at least one of the guiding, non-guiding and intermediate regions, except that the photorefractive dopant is not located solely in the guiding region; and (iii) exhibiting in said guiding region, intermediate region, or both, light guiding modes having different polarizations; and (b) exposing at least a part (10a, 10b) of the active optical waveguide to an effective transverse illumination of light (20) reacting with the photorefractive dopant and modifying said transverse refractive index profile; said part of the active optical waveguide being exposed to a fluence selectively suppressing the propagation of the light guiding modes having different polarizations so that the propagation of one mode is less suppressed than the propagation of the other mode(s). Such an active optical waveguide, single polarization mode optical waveguide lasers and multi-wavelength single polarization mode optical waveguide lasers comprising such an active optical waveguide, methods of their production, and their uses in telecommunications, in spectroscopy, in sensors and in absolute calibrated laser light sources.
Patent PT-990850-E (PT)
Inventor: PORCHER JEAN-MICHEL GEORGES MA
IPC: F01P1/08
Filed: 1999-09-30
Abstract: The pilot light fitting has a part (21) which connects with the water heater gas supply, an intermediate part (22), for mixing gas and air, and a terminal part (23) enveloping and sheltering the gas mixture combustion flame. The part (21) is supported, so that it can be removed, by one of the parts (30) of the gas supply of the water heater so that it can be withdrawn and refitted during maintenance. The part (21) has a split ring (40) which is elastically deformable. The perimeter of this ring (40) is increased, because of it flexibility, when it is removed and refitted during maintenance work. Retention in position of the part (21) is ensured by elastic closing the ring on the part (30) of the water heater. The split ring (40) has two free ends (42,43) situated opposite each other, near to which are feet (47,48) which enable the maintenance engineer to increase the perimeter of the part (21) at the time of its removal or fitting.
Patent PT-1064281-E (PT)
Inventor: COZZI PAOLO
IPC: C07D409/14
Filed: 1999-03-17
Abstract: Compounds which are benzoheterocyclic distamycin derivatives of formula (I), wherein n is 2, 3 or 4; A is a heteroatom selected from O and S or is a group NR, wherein R is hydrogen or C1-C4 alkyl; B is CH or N; R1 is hydrogen or C1-C4 alkyl; G is selected from the group consisting of (a, b, c, d, e, f, g, h, i, j), and -C=N; wherein R5, R6, R7, R8, R9, R10, R11 and R12 are, independently from each other, hydrogen or C1-C4 alkyl; T is a group of formula (II) or (III) as defined above, wherein p is 0 or 1; R2 and R3 are, independently from each other, hydrogen, C1-C4 alkyl optionally substituted by one or more fluorine atoms, or C1-C4 alkoxy; R4 is C1-C4 alkyl or C1-C3 haloalkyl; X1 and X2 are halogen atoms or pharmaceutically acceptable salts thereof; provided that at least one of R5, R6 and R7 is alkyl; are useful as antitumor agents.
Patent PT-1109504-E (PT)
Title: Electrosurgical device for cell necrosis induction
Inventor: LEE KEE S
IPC: A61M3/02
Filed: 1999-08-31
Abstract: A cell necrosis apparatus includes an introducer with a distal end sufficiently sharp to penetrate tissue. An energy delivery device has a first set of RF electrodes and a second set of RF electrodes. Each RF electrode of the first and second sets has a tissue piercing distal end and is positionable in the introducer as the introducer is advanced through tissue. The first and second sets of RF electrodes are deployable with curvature from the introducer. The second set of RF electrodes is deployable a greater distance from the introducer than the first set of RF electrodes.
Patent PT-1137943-E (PT)
Inventor: RUSSELL ROBERTSON JOHN
IPC: C12N5/09
Filed: 1999-12-10
Abstract: Sensitive and specific methods are provided for use in detecting the presence of cancer marker proteins in the body fluids of a mammal. Also provided are autoantibodies for use in these methods, and immortalized cells which are a source of the autoantibodies.
Patent PT-1139755-E (PT)
Inventor: ROSE LYNN M
IPC: A61K31/7048
Filed: 1999-12-16
Abstract: A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.
Patent SG-32093-G (SG)
Title: Circuit arrangement for processing video components
IPC: H04N9/64
Filed: 1993-03-23
Abstract: PCT No. PCT/EP88/00865 Sec. 371 Date May 25, 1989 Sec. 102(e) Date May 25, 1989 PCT Filed Sep. 27, 1988 PCT Pub. No. WO89/03155 PCT Pub. Date Apr. 6, 1989.A video signal processor as for generating a picture-in-picture signal, generates respective analog luminance components and first and second analog chrominance components. In order to reduce the system hardware and processing speed, multiplexing circuitry subsamples the luminance and chrominance components on a field basis to provide alternating fields of only luminance and only chrominance signal. The multiplexing circuitry further subsamples the chrominance components by providing groups of horizontal lines of only the first chrominance component alternating with groups of horizontal lines of only the second chrominance component.
Patent IE-780464-L (IE)
Title: Liposome compositions
IPC: A61K9/14
Filed: 1978-03-07
Abstract: Process for preparing a freeze-dried, potential liposome, mixture which comprises either (a) dissolving at least one liposome-forming amphipathic lipid, at least one biologically-active compound, and optionally one or more adjuvants, in a suitable solvent, and then freeze-drying the solution, or (b) preparing by any known method an aqueous liposome composition containing at least one biologically-active compound, and then freeze-drying the said aqueous liposome composition. Process for preparing an aqueous liposome composition which comprises dispersing said freeze-dried, potential liposome, mixture, obtained by procedure (a) or (b), in a suitable aqueous medium.
[US4311712A]
Patent IE-890639-L (IE)
Title: Perioperative use of an imidazole
IPC: A61K31/415
Filed: 1989-02-28
Abstract: 4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, known as medetomidine, and in particular its d-enantiomer and salts thereof are useful in perioperative care, in particular in reducing the amount of anaesthetic it is necessary to administer.
Patent FI-823836-L (FI)
Inventor: KUMAGAE YOJIRO
IPC: C07D401/06
Filed: 1982-11-09
Abstract: Chromogenic compounds of colorless or lightly colored form are disclosed having the following structural formula:  <IMAGE>  wherein X represents an optionally substituted aminophenyl, indolyl, julolidinyl, kairolyl, piperidinophenyl, pyrrolidinophenyl, morpholinyl, carbazolyl or indolizinyl radical. The compounds of this invention are eligible for use in pressure-sensitive and heat-sensitive record materials and manifold marking systems.
Patent FI-830192-L (FI)
Inventor: BURTON GEORGE
IPC: C07D499/00
Filed: 1983-01-20
Abstract: Preparation and use of 6,alpha-methoxy-6,beta-2-(2-methylphenoxycarbonyl)-2-(thien-3-yl) acetamido penicillanic acid of the formula 
<CHEM>
 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. 
<??>Intermediate of formula (X) 
<CHEM>
 and pharmaceutical composition comprising a penicillin of the first-mentioned formula, optionally with a clavulanic-acid derivative.
Patent IE-36621-L (IE)
Title: Acylation of cephalosporin esters
IPC: C07D/
Filed: 1972-08-02
Abstract: 1399349 Acylation of cephalosporin esters LILLY INDUSTRIES Ltd 7 Dec 1972 [11 Sept 1971] 42454/71 Heading C2C In a method for the acylation of the p-nitrobenzyl ester of 7-aminocephalosporanic acid or 7-aminodesacetoxycephalosporanic acid with a mixed anhydride, the acylation is carried out at a temperature between - 15 and - 50 C. and preferably between - 25 and - 45 C. The mixed anhydride may be of Formula I wherein R is C 1-4 alkyl ; R<SP>11</SP> is C 1-8 alkyl, or of Formula II or III in which W is S or O, Z is H, lower alkyl (C 1-3 ), CF 3 -, C 1-3 alkoxy, -OY, nitro, -NHR<SP>11</SP>, C 1-3 alkylamino, di-(C 1-3 )alkylamino, Cl, Br or F; X is -(CH 2 ) n -, -OCH 2 -, n is 0 or 1; Y is C 1-4 alkyl, benzyl, substituted benzyl or C 1-4 alkanoyl; and R<SP>111</SP> is of Formula VI, VII, VIII, IX or X A method of preparing cephalexin comprises acylating the p-nitrobenzyl ester of 7-aminodesacetoxycephalosporanic acid with a nitrogenblocked mixed anhydride of D-phenylglycine, the acylation being conducted between - 15 and - 50 C. and being followed by removal of the amino and carboxyl blocking groups. Suitable amino blocking groups are t-butoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl or an enamine formed by reacting the phenylglycine with an alkyl acetoacetate.
[GB1399349A]
Patent IE-45091-L (IE)
Title: INDOLIZINO [7,6,5-de] ISOQUINOLINE DERIVATIVES
IPC: C07D217/26
Filed: 1977-06-14
Abstract: Indolizino[7,6,5-de]isoquinoline derivatives of the general formula: <IMAGE> I wherein the symbol R1 represents a hydrogen atom, the symbol R2 represents a hydrogen atom, an amino radical, or a straight- or branched-chain alkyl radical which is optionally substituted on a terminal carbon atom by a vinyl, ethynyl, carboxy, alkoxycarbonyl, cyano, dialkoxymethyl, hydroxymethyl, dialkylaminomethyl (the alkyl radicals of which may form with the nitrogen atom to which they are attached a saturated five- or six-membered heterocyclic ring which may contain another hetero-atom selected from nitrogen, oxygen and sulphur, and - when a second nitrogen atom is present - may optionally be N-methylated) or trialkylammoniomethyl radical, or R2 represents a straight- chain alkyl radical which is substituted on the terminal carbon atom by an aminomethyl, alkylaminomethyl or hydroxyalkylaminomethyl radical, and the symbols R3 and R4 together form a valence bond, or the symbols R1 and R4 together form a valence bond and the symbols R2 and R3 together form a grouping of the general formula: <IMAGE> II wherein the group -OR5, which represents an alkoxy radical, is attached to the carbon atom situated in the alpha -position to the nitrogen atom carrying R3, the alkyl and alkoxy radicals, or moieties of groups, within the definition of symbols R2 and R5 containing from 1 to 4 carbon atoms and their salts are active as antimicrobial agents and antifungal agents, and are suitable for use as local antiseptics.
[US4137315A]
Patent IE-43249-L (IE)
Title: Drilling fluid weighting agent.
IPC: E21B21/00
Filed: 1976-06-25
Abstract: Weighting material for a drilling fluid, e.g. a drilling mud, is produced by firing iron oxide solids, e.g. iron oxide ores, calcined pyritic ores or iron-oxide-containing products of other metallurgical processes, in a circulating fluidized bed or rotary furnace at a temperature of 1210 DEG C to 1400 DEG C in an oxidizing atmosphere in which the oxygen content is augmented to transform magnetitic components to oxides of lower magnetic susceptibility. The product is then cooled slowly at least until it reaches a temperature of 780 DEG C, also in an oxidizing atmosphere. The weighting materials have extremely low magnetic susceptibility and thus can be used without interfering with inductive monitoring of the position of the drill string.
[US4092407A]
Patent IE-801832-L (IE)
Title: Lubricant retaining device
IPC: F16J15/54
Filed: 1980-08-29
Abstract: A lubricant retaining device for use with a gear case having a pair of matable sections with a shaft receiving opening therein. The lubricant retaining device extends inwardly to the interior of said case to reduce lubricant flow through said shaft receiving opening.
[US4347759A]
Patent IE-812335-L (IE)
Title: Trimming aid for an acetabular prothesis
IPC: A61F2/00
Filed: 1981-10-06
Abstract: To facilitate the trimming of flange 100 (FIG. 6) of a prosthesis 101 (FIG. 6) to fit closely into reamed out acetabulum 200 in hip bone 201, the aid comprises a body component 11 which corresponds in overall shape to socket member 102 (FIG. 6) of the prosthesis and a separate flange 13 having a protrusion 14 engageable alternatively into socket 12 in the body component 11 and socket 104 of the prothesis. The entire aid is alternately offered into the acetabulum 200 and removed for trimming its flange 13, this being repeated until a good fit of the flange 13 into the acetabulum 200 is achieved. Then, the flange 13, removed from the body component 11, is fitted to the prosthesis 101 (as in FIG. 6) and the flange 100 of the prosthesis can then be trimmed straight away accurately for fitting into the acetabulum 200.
[US4433686A]
Patent IE-45226-L (IE)
Title: New tetracarboxylic acid tetrachlorides
IPC: C07C233/65
Filed: 1981-10-08
Abstract: Dicarboxylic acid bis(3,5-dicarbamoyl-2,4,6-triiodoanilides) of the formula <IMAGE> wherein R1 is lower straight-chain or branched-chain mono- or polyhydroxyalkyl; R2 is hydrogen, lower alkyl or R1; R3 is hydrogen or lower alkyl; and X is a direct bond or straight-chain or branched-chain alkylene interrupted by one or more oxygen or substituted by hydroxy or lower alkyl, are useful in x-ray contrast media.
[US4239747A]
Patent IE-872502-L (IE)
Title: Monoclonal molecules which react immunologically with¹apolipoprotein a-1
IPC: G01N33/563
Filed: 1987-09-15
Abstract: Hybridomas and their secreted paratopic molecules that immunoreact with apolipoprotein A-I are disclosed, as are assay methods for determining the presence and amount of apo A-I, and diagnostic systems useful in performing those determinations. Monoclonal paratopic molecules secreted by hybridomas having ATCC accession numbers HB 9200, HB 9201, HB 9202, HB 9203 and HB 9204 are utilized.